Table 4.
Development of creatinine, eGFR, and proteinuria after start of ARV treatment
| All (N = 16) | TDF (N = 11) | AZT (N = 5) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Age (years), median (Q1, Q3) (min.–max.) | 37 (29, 47) | 34 (28, 46) | 46 (38, 48) | ||||||
| (21–55) | (21–55) | (36–48) | |||||||
| Duration of treatment (days), median (Q1, Q3) (min.–max.) | – | – | – | ||||||
| 220 (212, 231) | 219 (209, 232) | 222 (216, 232) | |||||||
| (134–240) | (134–240) | (212–235) | |||||||
| Before | After | P | Before | After | P | Before | After | P | |
| CD4-count/µL, mean (SD) | 259 (159) | 412 (177) | 0.004 | 263 (166) | 410 (187) | 0.019 | 252 (163) | 416 (170) | 0.159 |
| Creatinine (mg/dL), median (Q1, Q3) | 1.4 (1.0, 1.7) | 1.2 (1.1, 1.3) | 0.023 | 1.2 (1.0, 1.5) | 1.2 (1.0, 1.3) | 0.426 | 1.7 (1.7, 2.3) | 1.2 (1.2, 1.2) | 0.043 |
| eGFR (mL/min), mean (SD) | 68.4 (25.2) | 78.7 (18.3) | 0.060 | 79.0 (22.4) | 80.83 (20.6) | 0.730 | 45.1 (11.7) | 74.0 (12.3) | 0.009 |
| Proteinuria, n | 5 | 5 | – | 1 | 3 | – | 4 | 2 | – |
AZT = azidothymidine; eGFR = estimated glomerular filtration rate; TDF = tenovofir-diproxil fumarate.